These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30789308)

  • 21. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
    Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
    JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.
    Bohanec Grabar P; Rozman B; Tomsic M; Suput D; Logar D; Dolzan V
    Eur J Clin Pharmacol; 2008 Sep; 64(9):871-6. PubMed ID: 18496682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ABCB1 genetic polymorphisms affect opioid requirement by altering function of the intestinal P-glycoprotein.
    Qin W; Zhang L; Wang X; Liu B; Xu L; Liu L; Fan B
    Biomed Pharmacother; 2024 Jul; 176():116897. PubMed ID: 38850645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan.
    Mirzaev KB; Sychev DA; Ryzhikova KA; Konova OD; Mammaev SN; Gafurov DM; Shuev GN; Grishina EA; Sozaeva ZA
    Genet Test Mol Biomarkers; 2017 Dec; 21(12):747-753. PubMed ID: 29023140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between common CYP1A2 polymorphisms and theophylline metabolism in non-smoking healthy volunteers.
    Wang L; Hu Z; Deng X; Wang Y; Zhang Z; Cheng ZN
    Basic Clin Pharmacol Toxicol; 2013 Apr; 112(4):257-63. PubMed ID: 23167834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects.
    Pena MÁ; Muriel J; Saiz-Rodríguez M; Borobia AM; Abad-Santos F; Frías J; Peiró AM
    Clin Drug Investig; 2020 Jul; 40(7):617-628. PubMed ID: 32415468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers.
    Jensen BP; Roberts RL; Vyas R; Bonke G; Jardine DL; Begg EJ
    Br J Clin Pharmacol; 2012 Apr; 73(4):619-28. PubMed ID: 21999196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population.
    Hilli J; Rane A; Lundgren S; Bertilsson L; Laine K
    Fundam Clin Pharmacol; 2007 Aug; 21(4):379-86. PubMed ID: 17635176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects.
    Vizeli P; Schmid Y; Prestin K; Meyer Zu Schwabedissen HE; Liechti ME
    Eur Neuropsychopharmacol; 2017 Mar; 27(3):232-238. PubMed ID: 28117133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2.
    Han XM; Ouyang DS; Chen XP; Shu Y; Jiang CH; Tan ZR; Zhou HH
    Br J Clin Pharmacol; 2002 Nov; 54(5):540-3. PubMed ID: 12445035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of Genetic Polymorphisms on the Pharmacokinetics of Trazodone Hydrochloride: A Scoping Review and Future Perspective.
    Meulman J; Visacri MB; Moriel P; Pincinato EC
    Ther Drug Monit; 2023 Aug; 45(4):479-486. PubMed ID: 36191287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.
    Laika B; Leucht S; Heres S; Schneider H; Steimer W
    Pharmacogenomics J; 2010 Feb; 10(1):20-9. PubMed ID: 19636338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quercetin significantly inhibits the metabolism of caffeine, a substrate of cytochrome P450 1A2 unrelated to CYP1A2*1C  (-2964G>A) and *1F (734C>A) gene polymorphisms.
    Xiao J; Huang WH; Peng JB; Tan ZR; Ou-Yang DS; Hu DL; Zhang W; Chen Y
    Biomed Res Int; 2014; 2014():405071. PubMed ID: 25025048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clopidogrel pharmacogenetics: associations between genotype and stent thrombosis risk in patients with stent placement.
    Ferrari M; Tozzi M; Marino F; Tarallo A; Riva F; Mirabile M; Castelli P; Cosentino M
    J Cardiovasc Med (Hagerstown); 2019 Jan; 20(1):46-48. PubMed ID: 30531616
    [No Abstract]   [Full Text] [Related]  

  • 36. Association between pharmacokinetics of lenvatinib in healthy subjects and genetic polymorphisms of
    Song H; Bai W; Sun X; Qiu B; Guo N; Guo C; Hu Y; Dong Z
    Xenobiotica; 2021 Dec; 51(12):1463-1469. PubMed ID: 34979850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A semiphysiological population pharmacokinetic model of agomelatine and its metabolites in Chinese healthy volunteers.
    Xie F; Vermeulen A; Colin P; Cheng Z
    Br J Clin Pharmacol; 2019 May; 85(5):1003-1014. PubMed ID: 30761579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
    Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients.
    Serretti A; Calati R; Massat I; Linotte S; Kasper S; Lecrubier Y; Sens-Espel R; Bollen J; Zohar J; Berlo J; Lienard P; De Ronchi D; Mendlewicz J; Souery D
    Int Clin Psychopharmacol; 2009 Sep; 24(5):250-6. PubMed ID: 19593158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.